Switzerland - German - Tierarzneimittel Kompendium der Schweiz (Institut für Veterinärpharmakologie und toxikologie)

ebi-pharm ag - schwefel (hab) d4, vincetoxicum aus der asche der kräuter d30 (hab 6), vincetoxicum hirundinaria (hab) d6 - injektionslösung (s.c., i.c., i.m.) - schwefel (hab) d4 15.0 mg, schwefel (hab) d10 15.0 mg, vincetoxicum aus der asche der kräuter d30 (hab 6) 5,0 mg, vincetoxicum hirundinaria (hab) d6 als 30.0 mg, vincetoxicum hirundinaria (hab) d10 als 30.0 mg, vincetoxicum hirundinaria (hab) d30 als 30.0 mg, natrii chloridum, aqua ad iniectabilia, für glas 5 ml. - arzneimittel ohne indikation - andere komplementärarzneimittel

Switzerland - German - Tierarzneimittel Kompendium der Schweiz (Institut für Veterinärpharmakologie und toxikologie)

ebi-pharm ag - sulfur (hab) d4, vincetoxicum e cinere herbae d30 (hab 6), vincetoxicum hirundinaria (hab) d30 - tabletten - sulfur (hab) d4 36.0 mg, sulfur (hab) d10 36.0 mg, vincetoxicum e cinere herbae d30 (hab 6) 12.0 mg, vincetoxicum hirundinaria (hab) d6 72.0 mg, vincetoxicum hirundinaria (hab) d10 72.0 mg, vincetoxicum hirundinaria (hab) d30 72.0 mg, magnesii stearas, pro compresso. - zulassung mit reduziertem dossier ohne indikation nach art. 25 abs. 1 kpav (sr 812.212.24) - andere komplementärarzneimittel

Germany - German - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

chugai pharma germany gmbh (8186085) - lenograstim - pulver und lösungsmittel zur herstellung einer injektions- bzw. infusionslösung - teil 1 - pulver zur herstellung einer injektions- /infusionslösung; lenograstim (26855) 33,6 million i.e.

Switzerland - German - Swissmedic (Swiss Agency for Therapeutic Products)

boiron sa - vincetoxicum hirundinaria - d4, d; c2, d - homöopathisch

Switzerland - German - Swissmedic (Swiss Agency for Therapeutic Products)

boiron sa - vincetoxicum hirundinaria - tropfen / spray, trinkampullen, tabletten, trituration / pulver - c2, d, d4, d - homöopathisch

Switzerland - German - Swissmedic (Swiss Agency for Therapeutic Products)

boiron sa - vincetoxicum hirundinaria - c2, d, d4, d - homöopathisch

Switzerland - German - Swissmedic (Swiss Agency for Therapeutic Products)

boiron sa - vincetoxicum hirundinaria - k30, d; lm/q1, d; d2, d, c1, d - homöopathisch

European Union - German - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. siehe abschnitte 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

European Union - German - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastische mittel - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.

European Union - German - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastische mittel - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).